Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates.

Key Points

The aim is to develop linker-payloads that enhance the efficacy and stability of antibody-drug conjugates for cancer treatment.
Design of novel exatecan-amide linker-payloads
Evaluation of stability and aggregation characteristics
Testing efficacy against cancer models
Linker-payloads demonstrated low aggregation rates in in vitro tests, promoting stability.
High efficacy was noted in preliminary treatment assessments for cancer cell lines.

Novel linker-payloads show potential for enhancing cancer treatment with efficient antibody-drug conjugates, indicating a versatile platform.

. These linker-payloads are promising new leads for the treatment of cancer and represent a generalizable, modular, and advantageous linker platform.

No takes yet. Share an insight, caveat, or question.

Quiroz et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share